ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2678

EULAR Primary SjöGren’s Syndrome Disease Activity Index (ESSDAI), Results from the National Registry of the Spanish Society of Rheumatology (SJÖGRENSER)

José Rosas1, Carlos Sánchez-Piedra2, Monica Fernandez Castro3, Jose Luis Andreu4, Víctor Martínez Taboada5, Alejandro Olivé6,7, Enrique Judez8, Clara Moriano9, Vicente Torrente-Segarra10, Hector Corominas11, Blanca García Magallon12, Cristina Bohórquez Heras13, Javier Loricera14, Joaquin Maria Belzunegui Otano15, Carlos Guillén-Astete16, Ivan Castellvi17, José Miguel Senabre-Gallego1, Ana Pons1 and on behalf of SJOGRENSER project (GEEAS-SER), 1Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Rheumatology, Hospital Infanta Sofía, Madrid, Spain, 4Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 5Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, 6Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, 7Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 8Rheumatology Department. Hospital de Albacete, Albacete, Spain, 9Rheumatology, Hospital de León, Leon, Spain, 10Hospital de L'Hospitalet, L'Hospitalet de Llobregat, Spain, 11Hospital Sant Joan Despí Moisès Broggi, Barcelona, Spain, 12Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 13University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, 14Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 15Rheumatology, Donostia University Hospital, Donostia, Spain, 16Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, 17Rheumatology, Hospital Santa Creu i San Pau, Barcelona, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Sjogren's syndrome and registry

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Sjögren's Syndrome - Poster II: Clinical Science

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Primary Sjögren’s syndrome (PSS) is a systemic disease primarily characterized by lymphocytic infiltration of exocrine glands, but lymphocytic infiltration, can also can affect extraglandular tissues. Recently, it has been validated the EULAR SS disease activity index (ESSDAI), that is a clinical index that measure disease activity in PSS. The ESSDAI, includes 12 domains (organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, central nervous system, haematological, glandular, constitutional, lymphadenopathic, biological). The ESSDAI is now in use as a gold standard to measure disease activity in clinical studies, and as an outcome measure. The purpose of this study is to evaluate the ESSDAI baseline characteristics in a large Spanish multicenter registry of PSS.

Methods:  SJÖGRENSER, is a multicenter descriptive transversal study of a cohort of PSS patients fulfilling European/American consensus criteria 2012, collected from Rheumatology clinics all over Spain. Patients were included by randomisation from an anonymised list provided by every department. Two hundred and ninety eight variables were investigated: epidemiological, clinical, serological characteristics, treatments and complications. Specifically, ESSDAI domains were collected. The score may vary between 0-123. It is considered low activity an ESSDAI <5; moderate activity 5-13, and high activity if ESSDAI is ≥14. Variables were analysed by descriptive statistical methods, using means, medians, and rates, with their deviations and interquartile ranges (p25-p75).

Results:  Of 437 patients included, 95% were women, with median age (p25-75): 58.63 years (50,02-67,98 years), and age at diagnosis of 50.24 years (42,99-58,29 years), with a disease evolution of disease of 10.4 years (6-16 years). The median of diagnosis criteria of SS was 5 (4-5). Minor salivary gland biopsy was positive in 69%. Rheumatoid factor, AAN, anti-Ro/SSA and anti-La/SSB and cryoglobulins, were positive in 64,76%, 62,23 %, 93,59%, 67,05%, 3% of patients respectively. Cytopenia was present in 27% of patients and Beta-2 microglobulin serum levels was increased in 22% and C3/C4 reduced in 23% of patients. The median of ESSDAI of our population at enter to the study was 2 (0-4). In 31% of patients, ESSDAI, was 0, in 49% was concordant with low activity, moderate activity in 15% and 5% of patients show high activity. In table, the domains of ESSDAI, at enter to SJÖGREN-SER are shown. Table. ESSDAI results at enter at SJÖGRENSER cohort.

ESSDAI domains

SJÖGRENSER

N: 437

%

Constitutional

8

Lymphadenopathy

2

Glandular

4

Articular

35

Cutaneous

3

Pulmonary

6

Renal

5

Muscular

0,2

Peripheral nevous system

3

Central nervous system

2

Haematological

27

Biological

28

Conclusion:  1. In SJÖGRENSER, 20% of patients show moderate-high ESSDAI results and haematological, biological and articular domains are present in more than 10% of patients. 2. ESSDAI is a suitable tool to define and compare cohorts of patients with PSS.


Disclosure: J. Rosas, None; C. Sánchez-Piedra, None; M. Fernandez Castro, None; J. L. Andreu, None; V. Martínez Taboada, None; A. Olivé, None; E. Judez, None; C. Moriano, None; V. Torrente-Segarra, None; H. Corominas, None; B. García Magallon, None; C. Bohórquez Heras, None; J. Loricera, None; J. M. Belzunegui Otano, None; C. Guillén-Astete, None; I. Castellvi, None; J. M. Senabre-Gallego, None; A. Pons, None.

To cite this abstract in AMA style:

Rosas J, Sánchez-Piedra C, Fernandez Castro M, Andreu JL, Martínez Taboada V, Olivé A, Judez E, Moriano C, Torrente-Segarra V, Corominas H, García Magallon B, Bohórquez Heras C, Loricera J, Belzunegui Otano JM, Guillén-Astete C, Castellvi I, Senabre-Gallego JM, Pons A. EULAR Primary SjöGren’s Syndrome Disease Activity Index (ESSDAI), Results from the National Registry of the Spanish Society of Rheumatology (SJÖGRENSER) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/eular-primary-sjogrens-syndrome-disease-activity-index-essdai-results-from-the-national-registry-of-the-spanish-society-of-rheumatology-sjogrenser/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/eular-primary-sjogrens-syndrome-disease-activity-index-essdai-results-from-the-national-registry-of-the-spanish-society-of-rheumatology-sjogrenser/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.